Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Company Details
- Employees
- 97
- Founded
- -
- Address
- Parc Mazen-Sully, 6-8 Rue Pauline Kergomard,france
- Phone
- +33 (0)3 80 54 98 50
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- crossject.com
- HQ
- Dijon, Bourgogne
Crossject Questions
Crossject's helpline number is +33 (0)3 80 54 98 50
Crossject's website is crossject.com
Crossject's LinkedIn profile is https://fr.linkedin.com/company/crossject
Crossject has
97 employees.
View email and phone details for 97
employees at Crossject.
Crossject's industry is
Pharmaceutical Manufacturing
Crossject's top competitors are
Delpharm Dijon,
Adhexpharma,
Delpharm,
Urgo Group,
Laboratoires Urgo Healthcare,
Labtec,
Corden Pharma - A Full-Service Cdmo,
Adhex Technologies,
Astreapharma,
Crossject Pharma.
Crossject's categories are Pharmaceutical Manufacturing
Crossject's founding year is 2001
